Retrieved on:
Thursday, February 8, 2024
RA'ANANA, Israel, Feb. 8, 2024 /PRNewswire/ -- Inspira Technologies OXY BHN Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira"), a pioneer in life support technology with a vision to supersede traditional mechanical ventilators, has announced the signing of a non-binding Letter of Intent (LOI) with Shamir Medical Center (Assaf Harofeh), a renowned healthcare institution in central Israel. The Company plans to extend collaborations with further leading Israeli medical centers as part of a wider clinical deployment strategy.
Key Points:
- The Company plans to extend collaborations with further leading Israeli medical centers as part of a wider clinical deployment strategy.
- The LOI solidifies the mutual commitment of both parties to assess the integration and performance of the INSPIRA™ ART100 device ("Device) within Shamir Medical Center's clinical environment.
- This includes evaluating the device's fit with the hospital's clinical needs, efficiency in workflow, and overall impact on healthcare delivery.
- The evaluation will be led by Dr. Eduard Ilgiyaev, Director of the Intensive Care Unit at Shamir Medical Center and a leading pioneer of critical care medicine in Israel.
Retrieved on:
Thursday, December 28, 2023
The aggregate gross proceeds from the offering were approximately $3.88 million, before deducting placement agent fees and other estimated offering expenses.
Key Points:
- The aggregate gross proceeds from the offering were approximately $3.88 million, before deducting placement agent fees and other estimated offering expenses.
- The securities described above (excluding the unregistered warrants and the ordinary shares underlying the unregistered warrants) were offered and sold by the Company in a registered direct offering pursuant to a "shelf" registration statement on Form F-3 (Registration No.
- The offering of such securities in the registered direct offering were made only by means of a prospectus supplement that forms a part of the registration statement.
- A final prospectus supplement and an accompanying base prospectus relating to the registered direct offering was filed with the SEC and is available on the SEC's website located at http://www.sec.gov.
Retrieved on:
Wednesday, October 25, 2023
RA'ANANA, Israel, Oct. 25, 2023 /PRNewswire/ -- Inspira™ Technologies OXY BHN Ltd. (Nasdaq: IINN, IINNW) (the "Company" or "Inspira "), a company dedicated to advancing acute respiratory care by enabling breathing without lungs, announced today the grant of an additional patent by the U.S. Patent and Trademark Office for its respiratory medical device, the INSPIRATM ART500.
Key Points:
- RA'ANANA, Israel, Oct. 25, 2023 /PRNewswire/ -- Inspira™ Technologies OXY BHN Ltd. (Nasdaq: IINN, IINNW) (the "Company" or "Inspira "), a company dedicated to advancing acute respiratory care by enabling breathing without lungs, announced today the grant of an additional patent by the U.S. Patent and Trademark Office for its respiratory medical device, the INSPIRATM ART500.
- The newly granted patent relates to a novel automated self-priming module designed for the INSPIRA ART500 device.
- In addition to the United States, the Company has initiated patent applications in Europe and several countries in other regions.
- Inspira's CEO, Dagi Ben-Noon, commented: "We believe that this patent approval represents a further recognition of our unique solution alongside a major milestone towards the INSPIRATM ART500 system and building a global medical solution.
Retrieved on:
Tuesday, October 24, 2023
RA'ANANA, Israel, Oct. 24, 2023 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N.
Key Points:
- RA'ANANA, Israel, Oct. 24, 2023 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N.
- Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) - ("Inspira Technologies" or "the Company"), a company dedicated to advancing acute respiratory care by enabling breathing without lungs, today announces the termination of its at-the-market (ATM) equity offering program originally announced on April 4, 2023, taking effect immediately.
- Furthermore, Inspira Technologies wishes to assure stakeholders that its operations remain unaffected and uninterrupted by the ongoing war that started on October 7, 2023, involving the State of Israel (the "War") and the terror organization Hamas.
- The Company's workforce, customers, suppliers, and production facilities are currently insulated from the impact of the War.
Retrieved on:
Tuesday, October 10, 2023
The Company,
Death,
Agreement,
OXY,
CPB,
FDA,
CORP,
MED,
CIO,
Good,
Marketing,
Infection,
Ventilation,
Patient,
Food and Drug Administration,
Pharmaceutical industry,
Medical device RA'ANANA, Israel, Oct. 10, 2023 /PRNewswire/ -- Inspira™ Technologies OXY BHN Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), a company aiming to bring a paradigm shift to acute respiratory care by empowering breathing without lungs to minimize the need for mechanical ventilation systems, announced today that it had signed a distribution agreement (the "Agreement") with CIO MED GROUP, CORP., a leading technology and medical devices distributor in Central America.
Key Points:
- The Agreement to potentially generate $28 million, mainly in recurring revenues from disposable kits over five years, subject to the receipt of regulatory approval.
- The parties will collaborate on the marketing and the deployment of the INSPIRA™ ART device line and disposable kits in Central America.
- Currently, these patients require ventilation and oxygenation via external mechanical ventilation machinery that often causes multiple complications leading to physical damage, infection, and even death.
- Joe Hayon, president and co-founder of Inspira Technologies, stated, "In this Agreement, we are expanding our offering of innovative products to eight countries in Central America, led by Mexico."
Retrieved on:
Wednesday, September 13, 2023
Infection,
ART,
Ventilation,
Proton Inspira,
Patient,
OXY,
FDA,
Death,
Regulation of tobacco by the U.S. Food and Drug Administration,
Food,
Pharmaceutical industry RA'ANANA, Israel, Sept. 13, 2023 /PRNewswire/ -- Inspira™ Technologies OXY BHN Ltd. (Nasdaq: IINN, IINNW) (the "Company" or "Inspira Technologies"), a company aiming to bring a paradigm shift to acute respiratory care by empowering breathing without lungs, announced it had submitted its INSPIRA ART 100, a cardio-pulmonary bypass device, to the U.S. Food and Drug Administration (FDA) via the 510(k) pathway, with potential clearance expected during the first half of 2024.
Key Points:
- The Company's vision is to transform external breathing assistance for over 20 million patients each year that require ventilation and oxygenation via external mechanical ventilation machinery.
- Legacy systems for breathing assistance are causing multiple complications leading to physical damage, infection and possible death.
- "We are preparing for global deployments of our INSPIRA ART100 systems once FDA clearance is achieved.
- Our future systems can save millions of lives and change external respiratory aid for over 20 million people each year.
